Friday, 16 October 2026European Markets

STEF Stock Rises By 16% In The Last 5 Sessions

Loading stream...

(vianews) - shares of stef (cac 40: stf.pa) jumped by a staggering 16.8% in 5 sessions from 96.4 € to 112.60 € at 04:13 est on thursday, following the last session's upward trend. cac 40 is sliding 0.18% to 7,119.83 €, after three successive sessions in a row of losses.

about stef

stef sa provides temperature-controlled road transport and logistics services for agri-food manufacturers and retailers, and out-of-home foodservices. it transports fresh, frozen, and thermosensitive products; and seafood products. the company also provides maritime passenger and freight transport services between marseille and corsica; and co-packing services. it serves in france, italy, spain, portugal, belgium, the netherlands, and switzerland. the company was founded in 1920 and is headquartered in paris, france.

earnings per share

as for profitability, stef has a trailing twelve months eps of 5.86 €.

pe ratio

stef has a trailing twelve months price to earnings ratio of 19.22. meaning, the purchaser of the share is investing 19.22 € for every euro of annual earnings.

volume

today's last reported volume for stef is 7874 which is 286.54% above its average volume of 2037.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, stef's stock is considered to be oversold (<=20).

more news about stef (stf.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com